Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Advances in Therapy

Volumn 26, Issue 5, 2009, Pages 469-487

  Fabbri, Gianna ^a   Maggioni, Aldo Pietro ^a  

^a ANMCO RESEARCH CENTER   (Italy)

Author keywords

Cardiovascular risk factors; HDL C; Hypercholesterolemia; LDL C; Primary prevention; Secondary prevention; Statin therapy

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OXIDATION; PAIN; PHARYNGITIS; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PYRIMIDINES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 73449136164     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0025-6     Document Type: Review

References (100)

1. D. Yach C. Hawkes C.L. Gould K.J. Hofman 2004 The global burden of chronic diseases: overcoming impediments to prevention and control JAMA 291 2616 2622 15173153 10.1001/jama.291.21.2616 1:CAS:528:DC%2BD2cXkslWns78%3D (Pubitemid 38702780)
2. Cardiovascular diseases. Fact sheet no. 317. February 2007. World Health Organization web site. Available at: www.who.int. Accessed April 2009.
3. S.M. Grundy J.I. Cleeman C.N. Merz 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
4. Scandinavian Simvastatin Survival Study Group. 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1383 1389
5. Lipid Study Group. 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group N Engl J Med 339 1349 1357 10.1056/NEJM199811053391902 (Pubitemid 28509344)
6. Heart Protection Study Collaborative Group. 2002 MRC/BHF Heart Protection Study of cholesterol loweringwith simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial Lancet 360 7 22 10.1016/S0140-6736(02) 09327-3 (Pubitemid 34756487)
7. J.R. Downs M. Clearfield S. Weis 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1615 1622 9613910 10.1001/jama.279.20.1615 1:STN:280:DyaK1c3ntl2qsw%3D%3D (Pubitemid 28248586)
8. F.M. Sacks M.A. Pfeffer L.A. Moye 1996 Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1001 1009 8801446 10.1056/NEJM199610033351401 1:CAS:528:DyaK28XmsFWls7c%3D (Pubitemid 26338729)
9. J. Shepherd S.M. Cobbe I. Ford, et al. 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group N Engl J Med 333 1301 1317 7566020 10.1056/NEJM199511163332001 1:CAS:528:DyaK28Xhslemsw%3D%3D
10. C. Baigent A. Keech P.M. Kearney, et al. 2005 Cholesterol Treatment Trialist' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140- 6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
11. C.P. Cannon B.A. Steimberg S.A. Murphy, et al. 2006 Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 438 445 16875966 10.1016/j.jacc.2006.04.070 1:CAS:528:DC%2BD28XntlWjsLo%3D (Pubitemid 44109954)
12. J.C. LaRosa S.M. Grundy D.D. Waters, et al. 2005 Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435 15755765 10.1056/NEJMoa050461 1:CAS:528:DC%2BD2MXjtVWltrw%3D (Pubitemid 40471450)
13. J.A. De Lemos M.A. Blazing S.D. Wiviott, et al. 2004 A to Z Investigators. Early intensive vs a delayed conservative simvastin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 1307 1316 15337732 10.1001/jama.292.11.1307 (Pubitemid 39223221)
14. C.P. Cannon E. Braunwald C.H. McCabe, et al. 2004 Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction-22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndrome N Engl J Med 350 1495 1504 15007110 10.1056/NEJMoa040583 1:CAS:528:DC%2BD2cXjtVeqtr8%3D (Pubitemid 38477774)
15. T.R. Pedersen O. Faergeman J.J. Kastelein, et al. 2005 Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2437 2445 16287954 10.1001/jama.294.19.2437 1:CAS:528:DC%2BD2MXht1aku7jK (Pubitemid 41627921)
16. I. Graham D. Atar K. Borch-Johnsen, et al. 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 suppl.2 E1 E40 17726406 10.1097/01.hjr.0000277983.23934.c9 (Pubitemid 47339826)
17. R. Rosensen 2004 Statins: can the new generation make an impression? Expert Opin Emerg Drugs. 9 269 279 10.1517/14728214.9.2.269 (Pubitemid 39627129)
18. P. Libby 2005 The forgotten majority: unfinished business in cardiovascular risk reduction J Am Coll Cardiol. 46 1225 1228 16198835 10.1016/j.jacc.2005.07.006 (Pubitemid 41615541)
19. M.H. Davidson 2005 Reducing residual risk for patients on statin therapy: the potential role of combination therapy Am J Cardiol. 96 3K 13K 16291008 10.1016/j.amjcard.2005.08.002 1:CAS:528:DC%2BD2MXhtlGgs7vM (Pubitemid 41598106)
20. F.M. Sacks J.L. Rouleau L.A. Moye, et al. 1995 Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels Am J Cardiol 75 621 623 7887392 10.1016/S0002-9149(99)80631-6 1:STN:280:DyaK2M7ptlOlsQ%3D%3D
21. J. Shepherd G.J. Blauw M.B. Murphy 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial Lancet 360 1623 1630 12457784 10.1016/S0140-6736(02)11600-X 1:CAS:528:DC%2BD38XovFegt7o%3D (Pubitemid 35379733)
22. G.A. Kelley K.S. Kelley Z.V. Tran 2004 Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trial J Womens Health 13 1148 1164 10.1089/jwh.2004.13.1148
23. G.A. Kelley K.S. Kelley 2006 Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trial J Mens Health Gend 3 61 70 18645633 10.1016/j.jmhg.2005.09.003 (Pubitemid 43384010)
24. S. Yusuf S. Hawkan S. Ounpuu 2004 INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART Study): a case-control study Lancet 364 937 952 15364185 10.1016/S0140-6736(04)17018-9 (Pubitemid 39208455)
25. K.C. Zalesin B.A. Franklin W.M. Miller E.D. Peterson P.A. McCullough 2008 Impact of obesity on cardiovascular disease Endocrinol Metab Clin North Am 37 663 684,ix 18775358 10.1016/j.ecl.2008.06.004 1:CAS:528:DC%2BD1cXht1Kqs77L
26. P. Poirier T.D. Giles G.A. Bray 2006 Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss Arterioscler Thromb Vasc Biol 26 968 976 16627822 10.1161/01.ATV.0000216787.85457.f3 1:CAS:528: DC%2BD28XjsVersb4%3D (Pubitemid 43732100)
27. R. Scaglione C. Argano T. Di Chiara G. Licata 2004 Obesity and cardiovascular risk: the new public health problem of worldwide proportions Expert Rev Cardiovasc Ther 2 203 212 15151469 10.1586/14779072.2.2.203 (Pubitemid 38701979)
28. R. Ross 1999 Atherosclerosis - an inflammatory disease N Engl J Med 340 115 126 9887164 10.1056/NEJM199901143400207 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D (Pubitemid 29054847)
29. T.A. Pearson G.A. Mensach R.W. Alexander 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association Circulation 107 499 511 12551878 10.1161/01.CIR.0000052939.59093.45 (Pubitemid 36158056)
30. P.M. Ridker 2001 High-sensitivity C reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 1813 1818 11282915 1:CAS:528:DC%2BD3MXjsFKisbk%3D
31. P.M. Ridker N. Rifai L. Rose 2002 Comparison of C reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565 12432042 10.1056/NEJMoa021993 1:CAS:528:DC%2BD38Xos1KhsL0%3D (Pubitemid 35315836)
32. J.K. Pai T. Pischon J. Ma 2004 Inflammatory markers and the risk of coronary heart disease in men and women N Engl J Med 351 2599 2610 15602020 10.1056/NEJMoa040967 1:CAS:528:DC%2BD2cXhtV2qtbnE (Pubitemid 39628581)
33. S.D. de Ferranti N. Rifai 2007 C-reactive protein: a nontraditional serum marker of cardiovascular risk Cardiovasc Pathol 16 14 21 17218210 10.1016/j.carpath.2006.04.006 (Pubitemid 46049026)
34. P.M. Ridker R.J. Glynn C.H. Hennekens 1998 C-reactive protein: adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 2007 2011 9610529 1:STN:280: DyaK1c3nt1Slsg%3D%3D
35. P.M. Ridker 2007 C reactive protein and the prediction of cardiovascular events among those at intermediate risk moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2129 2138 17531663 10.1016/j.jacc.2007.02.052 1:CAS:528:DC%2BD2sXlvVOrsbo%3D (Pubitemid 46783865)
36. P.M. Ridker C.P. Cannon D. Morrow 2005 Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction (PROVE-IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 20 28 15635109 10.1056/NEJMoa042378 1:CAS:528:DC%2BD2MXis12msA%3D%3D (Pubitemid 40075677)
37. K.M. Field 2005 Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels Pharmacotherapy 25 1365 1377 16185181 10.1592/phco.2005.25.10.1365 1:CAS:528:DC%2BD2MXhtFGitbzF (Pubitemid 41407634)
38. P. Sakkinen R.D. Abbott J.D. Curb 2002 C-reactive protein and myocardial infarction J Clin Epidemiol 55 445 451 12007546 10.1016/S0895-4356(01)00502-9 (Pubitemid 34462239)
39. K.K. Ray C.P. Cannon 2005 The potential relevance of the multiple lipid independent (pleiotropic) effects of statins in the management of acute coronary syndromes J Am Coll Cardiol 46 1425 1433 16226165 10.1016/j.jacc.2005.05.086 1:CAS:528:DC%2BD2MXhtFWht7zE (Pubitemid 41446176)
40. P.M. Ridker N. Rifai M. Clearfield 2001 Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 1959 1965 11430324 10.1056/NEJM200106283442601 1:CAS:528:DC%2BD3MXltFersrc%3D (Pubitemid 32568149)
41. D.A. Morrow J.A. de Lemos M.S. Sabatine 2006 Clinical relevance of C-reactive protein during follow up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 281 288 16847150 10.1161/CIRCULATIONAHA.106.628909 1:CAS:528:DC%2BD28XntVSms70%3D (Pubitemid 44297094)
42. P.M. Ridker D.A. Morrow L.M. Rose 2005 Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/dl: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol 45 1644 1648 15893181 10.1016/j.jacc.2005.02.080 1:CAS:528:DC%2BD2MXktVOjtrs%3D (Pubitemid 40704500)
43. D.J. Gordon B.M. Rifklnd 1989 High density lipoprotein - the clinical implications of recent studies N Engl J Med 321 1311 1316 2677733 1:STN:280:DyaK3c%2FhsFSmsA%3D%3D
44. G. Assmann A.M. Gotto Jr 2004 HDL cholesterol and protective factors in atherosclerosis Circulation 109suppl.1 iii8 iii14
45. W.P. Castell R.J. Garrison P.W. Wilson 1986 Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study JAMA 256 2835 2838 10.1001/jama.256.20.2835 (Pubitemid 17178361)
46. P.K. Shah S. Kaul J. Nilsson 2001 Exploiting the vascular protective effects of high density lipoprotein and its apolipoproteins: an idea whose time for testing is coming part I Circulation 104 2376 2383 11696481 10.1161/hc4401.098467 1:CAS:528:DC%2BD3MXpt1WltrY%3D (Pubitemid 33049524)
47. J. Badimon V. Fuster 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1234 1241 2318976 10.1172/JCI114558 1:CAS:528:DyaK3cXitlehtbw%3D
48. P. Barter A.M. Gotto J.C. LaRosa 2007 Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events N Engl J Med 357 1301 1310 17898099 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M (Pubitemid 47481452)
49. P. Linsel Nitsche A.R. Tall 2005 HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat Rev Drug Discov 4 193 205 10.1038/nrd1658 (Pubitemid 40372554)
50. M.J. Chapman 2006 Therapeutic elevation of HDLcholesterol to prevent atherosclerosis and coronary artery disease Pharmacol Ther 11 893 908 10.1016/j.pharmthera.2006.02.003 (Pubitemid 44164383)
51. P. Barter A.M. Gotto J.C. LaRosa 2007 HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events N Engl J Med 357 1301 1310 17898099 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M (Pubitemid 47481452)
52. I.M. Singh M.H. Shishehbor B.J. Ansell 2007 High-density lipoproteins as a therapeutic target: a systematic review JAMA 298 786 798 17699012 10.1001/jama.298.7.786 1:CAS:528:DC%2BD2sXpt1Ghsr4%3D (Pubitemid 47263161)
53. D.J. Hausenloy D.M. Yellon 2008 Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart 94 706 714 18480348 10.1136/hrt.2007.125401 1:CAS:528:DC%2BD1cXnsFGhtbo%3D (Pubitemid 351744686)
54. S. Nissen J.C. Tardiff S. Nicholls 2007 Effect of the torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 17387129 10.1056/NEJMoa070635 1:CAS:528:DC%2BD2sXjsFGnsrY%3D (Pubitemid 46513296)
55. J.J. Kastelein S.I. van Leuven L. Burgess 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 1620 1630 17387131 10.1056/NEJMoa071359 1:CAS:528:DC%2BD2sXksFCmsb4%3D (Pubitemid 46631671)
56. M.L. Bots F.L. Visseren G.W. Evans 2007 RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 Study): a randomized double-blind trial Lancet 370 153 160 17630038 10.1016/S0140-6736(07)61088-5 1:CAS:528:DC%2BD2sXns12jtLg%3D (Pubitemid 47042895)
57. P.J. Barter M. Caulfield M. Eriksson 2007 ILLUMINATE Investigators. Effects of Torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 17984165 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL (Pubitemid 350146106)
58. B.J. Ansell K.E. Watson A.M. Fogelman 2005 High density lipoprotein function recent advances J Am Coll Cardiol 46 1792 1798 16286161 10.1016/j.jacc.2005.06.080 1:CAS:528:DC%2BD2MXht1SrtbzP (Pubitemid 41579798)
59. B.J. Ansell G.C. Fonarow A.M. Fogelman 2006 High density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 8 405 411 16901411 10.1007/s11883-006-0038-4 1:CAS:528:DC%2BD28XpslagsrY%3D (Pubitemid 44340185)
60. S.J. Nicholls 2008 HDL: still a target for new therapies? Curr Opin Investig Drugs 9 950 956 18729001 1:CAS:528:DC%2BD1cXhtFKntr7M
61. P. Jones M.H. Davidson E.A. Stein 2003 STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR*Trial) Am J Cardiol 92 152 160 12860216 10.1016/S0002-9149(03)00530-7 1:CAS:528:DC%2BD3sXlt1Wmsb8%3D (Pubitemid 36835963)
62. H. Schuster P.J. Barter S. Stender 2004 Effective Reductions In Cholesterol Using Rosuvastatin Therapy I study group. Effect of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study Am Heart J 147 705 713 15077101 10.1016/j.ahj.2003.10.004 1:CAS:528:DC%2BD2cXivVCrsLY%3D (Pubitemid 38900464)
63. B.G. Brown X.Q. Zhao A. Chait 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 11757504 10.1056/NEJMoa011090 1:CAS:528:DC%2BD3MXoslyhsLs%3D (Pubitemid 33126837)
64. M.J. Chapman 2004 Are the effect of statins on HDL cholesterol clinically relevant? Eur Heart J Suppl. 6 suppl.C c58 c63 10.1016/j.ehjsup.2004.04.002 1:CAS:528:DC%2BD2cXntVKisrc%3D (Pubitemid 38844954)
65. S.J. Nicholls 2008 Rosuvastatin and progression of atherosclerosis Expert Rev Cardiovasc Ther. 6 925 933 18666843 10.1586/14779072.6.7.925 1:CAS:528:DC%2BD1cXpt1ersrw%3D
66. M.L. Bots 2006 Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies Curr Med Res Opin. 22 2181 2190 17076979 10.1185/030079906X148472 (Pubitemid 44789983)
67. M.H. Davidson E. Dembowski 2008 Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep 10 521 525 18950564 10.1007/s11886-008-0081-6
68. D.T. Nash 2008 Use of vascular ultrasound in clinical trials to evaluate new cardiovascular therapies J Natl Med Assoc 100 222 229 18300539
69. J.J.P. Kastelein E. de Groot 2008 Ultrasound imaging techniques for the evaluation of cardiovascular therapies Eur Heart J 29 849 858 18334471 10.1093/eurheartj/ehn070
70. C.M. Ballantyne 1998 Clinical trial endpoints: angiograms, events and plaque instability Am J Cardiol 82 5M 11M 9766342 10.1016/S0002-9149(98)00591-8 1:CAS:528:DyaK1cXmslOltbw%3D
71. J.-C. Tardif T. Heinonen D. Orloff P. Libby 2006 Vascular biomarkers and surrogates in cardiovascular disease Circulation 113 2936 2942 16801474 10.1161/CIRCULATIONAHA.105.598987 (Pubitemid 44297235)
72. S.E. Nissen E.M. Tuzcu P. Schoenhagen 2004 REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial JAMA 291 1071 1080 14996776 10.1001/jama.291.9.1071 1:CAS:528:DC%2BD2cXhvFent78%3D (Pubitemid 38541684)
73. S.E. Nissen S.J. Nicholls I. Sipahi 2006 ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 1556 1565 16533939 10.1001/jama.295.13.jpc60002 1:CAS:528:DC%2BD28Xjt12itrc%3D
74. C.M. Ballantyne J.S. Raichlen J.S. Nicholls 2008 ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2458 2466 18378607 10.1161/CIRCULATIONAHA.108.773747 1:CAS:528:DC%2BD1cXltl2hsb8%3D (Pubitemid 351670452)
75. S.J. Nicholls E.M. Tuzcu I. Sipahi 2007 Statins, highdensity lipoprotein cholesterol and regression of coronary atherosclerosis JAMA 297 499 508 17284700 10.1001/jama.297.5.499 1:CAS:528:DC%2BD2sXhs1Wis7k%3D (Pubitemid 46220805)
76. P. Amarenco J. Labreuche P. Lavallee P.J. Touboul 2004 Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis Stroke 35 2902 2009 15514180 10.1161/01.STR.0000147965.52712.fa 1:CAS:528:DC%2BD2cXpvVGkt78%3D (Pubitemid 39565192)
77. T.J. Smilde S. van Wissen H. Wollersheim 2001 Effect of aggressive versus conventional lipid lowering on Atherosclerosis Progression in Familial Hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 577 581 11558482 10.1016/S0140-6736(00)04053-8 1:CAS:528: DC%2BD3MXhsVKltbo%3D (Pubitemid 32179609)
78. A.J. Taylor S.M. Kent P.J. Flaherty 2002 ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2055 2060 12379573 10.1161/01.CIR.0000034508. 55617.65 1:CAS:528:DC%2BD38Xns1Sns7c%3D (Pubitemid 35192810)
79. J.R. Crouse J.S. Raichlen W.A. Riley 2007 METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low risk individuals with subclinical atherosclerosis JAMA 297 1344 1353 17384434 10.1001/jama.297.12.1344 1:CAS:528:DC%2BD2sXjs1ejtLw%3D (Pubitemid 46513235)
80. S.J. Nicholls J.S. Raichlen C.M. Ballantyne 2008 Intravascular ultrasound evaluation of the effect of rosuvastatin versus atorvastatin on progression of coronary atherosclerosis: design of the SATURN study Atheroscler Suppl 9 202 10.1016/S1567-5688(08)70808-0
81. P.M. Ridker E. Danielson F.A.H. Fonseca 2008 JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
82. P.M. Ridker E. Danielson F.A.H. Fonseca 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 1182 19329177 10.1016/S0140-6736(09)60447-5 1:CAS:528:DC%2BD1MXktV2gsL8%3D
83. R.J. Glynn E. Danielson F.A.H. Fonseca 2009 A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med. 2009 Mar 29 360 1851 1861 1:CAS:528:DC%2BD1MXlsVSlurk%3D
84. M.A. Hlatky 2008 Expanding the orbit of primary prevention: moving beyond JUPITER N Engl J Med 359 2280 2282 18997195 10.1056/NEJMe0808320 1:CAS:528:DC%2BD1cXhtl2gurbJ
85. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
86. H. Soran P. Durrington 2008 Rosuvastatin: efficacy,safety and clinical effectiveness Expert Opin Pharmacother 9 2145 2160 18671469 10.1517/14656566.9. 12.2145 1:CAS:528:DC%2BD1cXpt1SmsL8%3D
87. M.S. Kostapanos H.J. Milionis M.S. Elisaf 2008 An overview of the extra-lipid effects of rosuvastatin J Cardiovasc Pharmacol Ther 13 157 174 18460672 10.1177/1074248408318628 1:CAS:528:DC%2BD1cXhtVOgu7nK
88. K. Ramasubbu J. Estep D.L. White 2008 Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy J Am Coll Cardiol 5 415 426 10.1016/j.jacc.2007.10.009
89. W.C. Levy 2008 Observational studies of statins in systolic heart failure Heart Fail Clin 4 201 208 18433700 10.1016/j.hfc.2008.01.006 (Pubitemid 351539132)
90. H. Krum R. Latini A.P. Maggioni 2007 Statins and symptomatic chronic systolic heart failure: a posthoc analysis of 5010 patients enrolled in Val-HeFT Int J Cardiol 119 48 53 17049646 10.1016/j.ijcard.2006.07.106 (Pubitemid 46830817)
91. J. Kjeskus E. Apetrei V. Barrios 2007 CORONA Group. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2248 2261 10.1056/NEJMoa0706201 (Pubitemid 350190755)
92. Task Force for DiagnosisTreatment of AcuteChronic Heart Failure 2008 of European Society of Cardiology K. Dickstein A. Cohen-Solal 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2388 2442 18799522 10.1093/eurheartj/ehn309 1:CAS:528:DC%2BD1cXhtlGisbvO
93. GISSI-HF Investigators L. Tavazzi A.P. Maggioni 2008 Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial Lancet 372 1231 1239 18757089 10.1016/S0140-6736(08)61240-4
94. G. Fornarow 2008 Statins and n-3 supplementation in heart failure Lancet 37 1195 1196 10.1016/S0140-6736(08)61241-6
95. S.R. Selger N.S. Weiss D.L. Gillen 2002 HMG CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney Int 61 297 304 10.1046/j.1523-1755.2002.00109.x (Pubitemid 34075157)
96. C. Wanner V. Krane W. März 2005 German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med. 353 238 248 16034009 10.1056/NEJMoa043545 1:CAS:528:DC%2BD2MXmt1Kms7s%3D (Pubitemid 41058323)
97. B. Fellström F. Zannad R. Schmieder 2005 AURORA study group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study Curr Control Trials Cardiovasc Med 6 9 15910680 10.1186/1468-6708-6-9 (Pubitemid 41535314)
98. B.C. Fellström A.G. Jardine R.E. Schmieder 2009 Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 1395 1407 19332456 10.1056/NEJMoa0810177
99. G.F.M. Strippoli J.C. Craig 2009 Sunset for statins after AURORA N Engl J Med 360 1455 1457 19332454 10.1056/NEJMe0901067 1:CAS:528:DC%2BD1MXjvFGhsbo%3D
100. S. Mora K. Musunuru R.S. Blumenthal 2009 The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines Clin Chem 55 219 228 19095730 10.1373/clinchem.2008.109728 1:CAS:528:DC%2BD1MXhvVWksrc%3D